How much funding has Assembly Biosciences raised?

Assembly Biosciences has raised $217.7M in total funding, most recently a Venture Round.

Who are Assembly Biosciences's investors?

Assembly Biosciences's investors include Gilead Sciences, Armistice Capital, Commodore Capital, Farallon Capital, Janus Henderson Investors, RA Capital Management.

When was Assembly Biosciences founded?

Assembly Biosciences was founded in 2012.

Where is Assembly Biosciences headquartered?

Assembly Biosciences is headquartered in South San Francisco, California, United States.

What industry is Assembly Biosciences in?

Assembly Biosciences operates in Biotech, Healthcare.

How many employees does Assembly Biosciences have?

Assembly Biosciences has 51-200 employees.

Assembly Biosciences

IPO

Home - Assembly Bio

Public · South San Francisco, United States · Founded 2012 · $217.7M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2012
Business Model: B2B
Website: assemblybio.com

Total Funding: $217.7M
Last Round: $175.0M Venture RoundAug 2025
Rounds: 3
Type: Public

About

Assembly Biosciences is a clinical-stage biotechnology company dedicated to developing innovative small-molecule antiviral therapeutics targeting serious viral diseases. The company's pipeline focuses on recurrent genital herpes, chronic hepatitis delta virus (HDV), and chronic hepatitis B (HBV). Assembly Bio partners with Gilead Sciences to advance novel antiviral treatments with the potential to change disease outcomes for patients worldwide.

Summary

Assembly Biosciences is a Biotech company based in South San Francisco, United States, founded in 2012. It has raised $217.7M in total across 3 rounds, most recently a $175.0M Venture Round round in Aug 2025. Investors include Gilead Sciences, Armistice Capital and Commodore Capital.

LinkedIn X (Twitter)